From hypertension to heart failure: update on the management of systolic and diastolic dysfunction.

[1]  Márta Hogye,et al.  [Management of chronic heart failure]. , 2005, Orvosi hetilap.

[2]  M. Konstam.  "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. , 2003, Journal of cardiac failure.

[3]  M. Jessup,et al.  Heart failure. , 2003, The New England journal of medicine.

[4]  J. Gardin,et al.  Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.

[5]  I. Piña,et al.  Metoprolol CR/XL in Female Patients With Heart Failure: Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) , 2002, Circulation.

[6]  E. Antman,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary , 2002 .

[7]  Alan C. Wilson,et al.  Time trends in the occurrence and outcome of acute myocardial infarction and coronary heart disease death between 1986 and 1996 (a New Jersey statewide study). , 2001, The American journal of cardiology.

[8]  B. Fagerberg,et al.  Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. , 2001, Journal of the American College of Cardiology.

[9]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[10]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[11]  S. Yusuf,et al.  HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. , 2000, Pharmacotherapy.

[12]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[13]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[14]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[15]  H. Dargie,et al.  The Cardiac Insufficiency Bisoprolol Study II , 1999, The Lancet.

[16]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[17]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[18]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[19]  R. Vasan,et al.  The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. , 1996, Archives of internal medicine.

[20]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.